LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management - PubMed (original) (raw)
LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management
William C Cromwell et al. J Clin Lipidol. 2007 Dec.
Abstract
Background: The cholesterol content of LDL particles is variable, causing frequent discrepancies between concentrations of LDL cholesterol and LDL particle number. In managing patients at risk for cardiovascular disease (CVD) to LDL target levels, it is unclear whether LDL cholesterol provides the optimum measure of residual risk and adequacy of LDL lowering treatment.
Objective: To compare the ability of alternative measures of LDL to provide CVD risk discrimination at relatively low levels consistent with current therapeutic targets.
Methods: Concentrations of LDL cholesterol (LDL-C) and non-HDL cholesterol (non-HDL-C) were measured chemically and LDL particle number (LDL-P) and VLDL particle number (VLDL-P) were measured by nuclear magnetic resonance (NMR) in 3066 middle-aged white participants (53% women) without CVD in the Framingham Offspring cohort. The main outcome measure was incidence of first CVD event.
Results: At baseline, the cholesterol content per LDL particle was negatively associated with triglycerides and positively associated with LDL-C. On follow-up (median 14.8 yrs), 265 men and 266 women experienced a CVD event. In multivariable models adjusting for non-lipid CVD risk factors, LDL-P was related more strongly to future CVD in both sexes than LDL-C or non-HDL-C. Subjects with a low level of LDL-P (<25(th) percentile) had a lower CVD event rate (59 events per 1000 person-years) than those with an equivalently low level of LDL-C or non-HDL-C (81 and 74 events per 1000 person-years, respectively).
Conclusions: In a large community-based sample, LDL-P was a more sensitive indicator of low CVD risk than either LDL-C or non-HDL-C, suggesting a potential clinical role for LDL-P as a goal of LDL management.
Figures
Figure 1
Cholesterol content of LDL particles in subgroups defined by levels of LDL cholesterol (LDL-C) and triglycerides (data from Table 2). Numbers indicate mean LDL size (nm) within each subgroup.
Figure 2
Event-free survival among participants with LDL cholesterol (LDL-C) and LDL particle number (LDL-P) above or below the median. Median values were 131 mg/dL for LDL-C and 1414 nmol/L for LDL-P.
Similar articles
- Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence.
Aday AW, Lawler PR, Cook NR, Ridker PM, Mora S, Pradhan AD. Aday AW, et al. Circulation. 2018 Nov 20;138(21):2330-2341. doi: 10.1161/CIRCULATIONAHA.118.035432. Circulation. 2018. PMID: 30021845 Free PMC article. - Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
Bartlett J, Predazzi IM, Williams SM, Bush WS, Kim Y, Havas S, Toth PP, Fazio S, Miller M. Bartlett J, et al. Circ Cardiovasc Qual Outcomes. 2016 May;9(3):206-212. doi: 10.1161/CIRCOUTCOMES.115.002436. Epub 2016 May 10. Circ Cardiovasc Qual Outcomes. 2016. PMID: 27166203 Free PMC article. - Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.
Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D'Agostino RB, Vasan RS, Robins SJ. Kathiresan S, et al. Circulation. 2006 Jan 3;113(1):20-9. doi: 10.1161/CIRCULATIONAHA.105.567107. Epub 2005 Dec 27. Circulation. 2006. PMID: 16380547 - Update on the laboratory investigation of dyslipidemias.
Ramasamy I. Ramasamy I. Clin Chim Acta. 2018 Apr;479:103-125. doi: 10.1016/j.cca.2018.01.015. Epub 2018 Jan 11. Clin Chim Acta. 2018. PMID: 29336935 Review. - Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ, Watson KE, Talbert RL. Cziraky MJ, et al. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. J Manag Care Pharm. 2008. PMID: 19891279 Review.
Cited by
- Clinical Relevance of Nuclear Magnetic Resonance LipoProfile.
Emeasoba EU, Ibeson E, Nwosu I, Montemarano N, Shani J, Shetty VS. Emeasoba EU, et al. Front Nucl Med. 2022 Jul 13;2:960522. doi: 10.3389/fnume.2022.960522. eCollection 2022. Front Nucl Med. 2022. PMID: 39354981 Free PMC article. Review. - Apolipoproteins, lipids, lipid-lowering drugs and risk of amyotrophic lateral sclerosis and frontotemporal dementia: a meta-analysis and Mendelian randomisation study.
Chalitsios CV, Ley H, Gao J, Turner MR, Thompson AG. Chalitsios CV, et al. J Neurol. 2024 Oct;271(10):6956-6969. doi: 10.1007/s00415-024-12665-x. Epub 2024 Sep 4. J Neurol. 2024. PMID: 39230722 Free PMC article. Review. - Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024.
Bays HE, Kirkpatrick C, Maki KC, Toth PP, Morgan RT, Tondt J, Christensen SM, Dixon D, Jacobson TA. Bays HE, et al. Obes Pillars. 2024 Mar 12;10:100108. doi: 10.1016/j.obpill.2024.100108. eCollection 2024 Jun. Obes Pillars. 2024. PMID: 38706496 Free PMC article. - Association of non-HDL-C/apoB ratio with long-term mortality in the general population: A cohort study.
Zhang K, Wei C, Shao Y, Wang L, Zhao Z, Yin S, Tang X, Li Y, Gou Z. Zhang K, et al. Heliyon. 2024 Mar 15;10(6):e28155. doi: 10.1016/j.heliyon.2024.e28155. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38545184 Free PMC article. - Palm-based tocotrienol-rich fraction (TRF) supplementation modulates cardiac sod1 expression, fxr target gene expression, and tauro-conjugated bile acid levels in aleptinemic mice fed a high-fat diet.
Md Shahrulnizam NAN, Mohd Efendy Goon MD, Ab Rahim S, Lew SW, Sheikh Abdul Kadir SH, Ibrahim E. Md Shahrulnizam NAN, et al. Genes Nutr. 2024 Feb 27;19(1):3. doi: 10.1186/s12263-024-00742-9. Genes Nutr. 2024. PMID: 38413846 Free PMC article.
References
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. - PubMed
- Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apoB levels. Atherosclerosis. 1991;89:109–16. - PubMed
- Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847–70. - PubMed
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–97. - PubMed
- Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39. - PubMed
Grants and funding
- K24 HL004334/HL/NHLBI NIH HHS/United States
- K24 HL004334-02/HL/NHLBI NIH HHS/United States
- N01 HC025195/HC/NHLBI NIH HHS/United States
- N01HC25195/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources